Order Article Reprints

Ślusarczyk A, Bryant HE, Chen E, Hitchcock I, Zeidler M, Chantry A, Thomas S. Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment. Medical Sciences Forum. 2021; 3(1):17. https://doi.org/10.3390/IECC2021-09209

Ślusarczyk, Aleksander, Helen E. Bryant, Edwin Chen, Ian Hitchcock, Martin Zeidler, Andrew Chantry, and Sally Thomas. 2021. "Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment" Medical Sciences Forum 3, no. 1: 17. https://doi.org/10.3390/IECC2021-09209

Ślusarczyk, A., Bryant, H. E., Chen, E., Hitchcock, I., Zeidler, M., Chantry, A., & Thomas, S. (2021). Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment. Medical Sciences Forum, 3(1), 17. https://doi.org/10.3390/IECC2021-09209